Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline

Current securities

1. SCHEDULE 13G/A filingAug 14, 2026
2. 10-Q filingAug 12, 2026
3. Results of Operations and Financial ConditionAug 10, 2026
4. Entry into a Material Definitive AgreementJul 2, 2026
5. 424B5 filingJul 2, 2026